Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 188

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface

Open access
Van Molle, Inge, Thomann, Andreas, Buckley, Dennis L., So, Ernest C., Lang, Steffen, Crews, Craig M., Ciulli, Alessio·2012·Chemistry & Biology

Abstract

SUMMARY Fragment screening is widely used to identify attractive starting points for drug design. However, its potential and limitations to assess the tractability of often challenging protein:protein interfaces have been underexplored. Here, we address this question by means of a systematic deconstruction of lead-like inhibitors of the pVHL:HIF-1α interaction into their component fragments. Using biophysical techniques commonly employed for screening, we could only detect binding of fragments that violate the Rule of Three, are more complex than those typically screened against classical druggable targets, and occupy two adjacent binding subsites at the interface rather than just one. Analyses based on ligand and group lipophilicity efficiency of anchored fragments were applied to dissect the individual subsites and probe for binding hot spots. The implications of our findings for targeting protein interfaces by fragment-based approaches are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chembiol.2012.08.015

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 43

  1. Babaoglu, 2006, Deconstructing fragment-based inhibitor discovery, Nat. Chem. Biol., 2, 720, 10.1038/nchembio831 · DOI · Paper page
  2. Barelier, 2010, Fragment-based deconstruction of Bcl-xL inhibitors, J. Med. Chem., 53, 2577, 10.1021/jm100009z · DOI
  3. Basse, 2010, Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant, Chem. Biol., 17, 46, 10.1016/j.chembiol.2009.12.011 · DOI · Paper page
  4. Braisted, 2003, Discovery of a potent small molecule IL-2 inhibitor through fragment assembly, J. Am. Chem. Soc., 125, 3714, 10.1021/ja034247i · DOI · Paper page
  5. Ciulli, 2007, Fragment-based approaches to enzyme inhibition, Curr. Opin. Biotechnol., 18, 489, 10.1016/j.copbio.2007.09.003 · DOI
  6. Ciulli, 2006, Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods, J. Med. Chem., 49, 4992, 10.1021/jm060490r · DOI
  7. Congreve, 2003, A ‘rule of three’ for fragment-based lead discovery?, Drug Discov. Today, 8, 876, 10.1016/S1359-6446(03)02831-9 · DOI · Paper page
  8. Congreve, 2008, Recent developments in fragment-based drug discovery, J. Med. Chem., 51, 3661, 10.1021/jm8000373 · DOI · Paper page
  9. Coyne, 2010, Drugging challenging targets using fragment-based approaches, Curr. Opin. Chem. Biol., 14, 299, 10.1016/j.cbpa.2010.02.010 · DOI
  10. Crews, 2010, Targeting the undruggable proteome: the small molecules of my dreams, Chem. Biol., 17, 551, 10.1016/j.chembiol.2010.05.011 · DOI · Paper page
  11. Dalvit, 2001, WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability, J. Biomol. NMR, 21, 349, 10.1023/A:1013302231549 · DOI · Paper page
  12. Edfeldt, 2011, Fragment screening to predict druggability (ligandability) and lead discovery success, Drug Discov. Today, 16, 284, 10.1016/j.drudis.2011.02.002 · DOI · Paper page
  13. Erlanson, 2000, Site-directed ligand discovery, Proc. Natl. Acad. Sci. USA, 97, 9367, 10.1073/pnas.97.17.9367 · DOI · Paper page
  14. Erlanson, 2004, Fragment-based drug discovery, J. Med. Chem., 47, 3463, 10.1021/jm040031v · DOI · Paper page
  15. Fauman, 2011, Structure-based druggability assessment—identifying suitable targets for small molecule therapeutics, Curr. Opin. Chem. Biol., 15, 463, 10.1016/j.cbpa.2011.05.020 · DOI · Paper page
  16. Hajduk, 2007, A decade of fragment-based drug design: strategic advances and lessons learned, Nat. Rev. Drug Discov., 6, 211, 10.1038/nrd2220 · DOI · Paper page
  17. Hajduk, 2005, Druggability indices for protein targets derived from NMR-based screening data, J. Med. Chem., 48, 2518, 10.1021/jm049131r · DOI · Paper page
  18. Hajduk, 2011, Drug discovery: A question of library design, Nature, 470, 42, 10.1038/470042a · DOI
  19. Higueruelo, 2009, Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database, Chem. Biol. Drug Des., 74, 457, 10.1111/j.1747-0285.2009.00889.x · DOI
  20. Hopkins, 2004, Ligand efficiency: a useful metric for lead selection, Drug Discov. Today, 9, 430, 10.1016/S1359-6446(04)03069-7 · DOI · Paper page
  21. Kaelin, 2008, The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer, Nat. Rev. Cancer, 8, 865, 10.1038/nrc2502 · DOI · Paper page
  22. Kozakov, 2011, Structural conservation of druggable hot spots in protein-protein interfaces, Proc. Natl. Acad. Sci. USA, 108, 13528, 10.1073/pnas.1101835108 · DOI · Paper page
  23. Köster, 2011, A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes, J. Med. Chem., 54, 7784, 10.1021/jm200642w · DOI
  24. Kranz, 2011, Protein thermal shifts to identify low molecular weight fragments, Methods Enzymol., 493, 277, 10.1016/B978-0-12-381274-2.00011-X · DOI
  25. Larsson, 2011, Efficiency of hit generation and structural characterization in fragment-based ligand discovery, Curr. Opin. Chem. Biol., 15, 482, 10.1016/j.cbpa.2011.06.008 · DOI
  26. Loenarz, 2009, Evidence for a stereoelectronic effect in human oxygen sensing, Angew. Chem. Int. Edit. Engl., 48, 1784, 10.1002/anie.200805427 · DOI
  27. Lundquist, 2002, The cluster glycoside effect, Chem. Rev., 102, 555, 10.1021/cr000418f · DOI · Paper page
  28. Mayer, 1999, Characterization of ligand binding by saturation transfer difference NMR spectroscopy, Angew. Chem. Int. Edit. Engl., 38, 1784, 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q · DOI · Paper page
  29. Min, 2002, Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling, Science, 296, 1886, 10.1126/science.1073440 · DOI · Paper page
  30. Mortenson, 2011, Assessing the lipophilicity of fragments and early hits, J. Comput. Aided Mol. Des., 25, 663, 10.1007/s10822-011-9435-z · DOI
  31. Murray, 2002, The consequences of translational and rotational entropy lost by small molecules on binding to proteins, J. Comput. Aided Mol. Des., 16, 741, 10.1023/A:1022446720849 · DOI · Paper page
  32. Murray, 2009, The rise of fragment-based drug discovery, Nat. Chem., 1, 187, 10.1038/nchem.217 · DOI · Paper page
  33. Murray, 2012, Experiences in fragment-based drug discovery, Trends Pharmacol. Sci., 33, 224, 10.1016/j.tips.2012.02.006 · DOI · Paper page
  34. Nazaré, 2012, Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes, Angew. Chem. Int. Edit. Engl., 51, 905, 10.1002/anie.201107091 · DOI
  35. Page, 1971, Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect, Proc. Natl. Acad. Sci. USA, 68, 1678, 10.1073/pnas.68.8.1678 · DOI · Paper page
  36. Petros, 2006, Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis, J. Med. Chem., 49, 656, 10.1021/jm0507532 · DOI · Paper page
  37. Saxty, 2007, Identification of inhibitors of protein kinase B using fragment-based lead discovery, J. Med. Chem., 50, 2293, 10.1021/jm070091b · DOI
  38. Stout, 1998, The additivity of substrate fragments in enzyme-ligand binding, Structure, 6, 839, 10.1016/S0969-2126(98)00086-0 · DOI
  39. Śledź, 2011, From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1, Angew. Chem. Int. Edit. Engl., 50, 4003, 10.1002/anie.201008019 · DOI
  40. Teotico, 2009, Docking for fragment inhibitors of AmpC beta-lactamase, Proc. Natl. Acad. Sci. USA, 106, 7455, 10.1073/pnas.0813029106 · DOI
  41. Tsao, 2006, Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design, Bioorg. Med. Chem., 14, 7953, 10.1016/j.bmc.2006.07.050 · DOI
  42. Wells, 2007, Reaching for high-hanging fruit in drug discovery at protein-protein interfaces, Nature, 450, 1001, 10.1038/nature06526 · DOI · Paper page
  43. Yin, 2005, Strategies for targeting protein-protein interactions with synthetic agents, Angew. Chem. Int. Edit. Engl., 44, 4130, 10.1002/anie.200461786 · DOI · Paper page

Cited by

See all 188

Metadata

Authors
Van Molle, I., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A.
Venue
Chemistry & Biology
Publisher
Elsevier BV
Published
2012-10
Volume
19
Issue
10
Pages
1300-1312
ISSN
1074-5521 (ISSN-L)
OpenAlex
W2065136554
Cited by
188
References
9
FWCI
9.50
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface. https://app.cochat.ai/papers/10.1016/j.chembiol.2012.08.015
The paper
Van Molle, I., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A. (2012). Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface. Chemistry & Biology. https://doi.org/10.1016/j.chembiol.2012.08.015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.